Toxoplasma encephalitis: Influence of the vehicle on the efficacy of different doses of 2′,3′-dideoxyinosine in mice

Parasite

Volumn 7, Issue 1, 2000, Pages 39-42

  Gherardi, A ^a   Sarciron, M E ^a   Peyron, F ^b  

^a UNIVERSITÉ LYON 1   (France)

^b CROIX ROUSSE HOSPITAL   (France)

Author keywords

2 ,3 dideoxyinosine; Mice; Toxoplasma gondii; Toxoplasmosis; Vehicle

Indexed keywords

MURINAE; TOXOPLASMA; TOXOPLASMA GONDII;

ANTACID AGENT; BUFFER; DIDANOSINE;

ANIMAL; ARTICLE; DISEASE MODEL; DOSE RESPONSE; DRUG FORMULATION; ENCEPHALITIS; FEMALE; METHODOLOGY; MOUSE; TOXOPLASMA; TOXOPLASMOSIS;

ANIMALS; ANTACIDS; BUFFERS; DIDANOSINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; ENCEPHALITIS; FEMALE; MICE; TOXOPLASMA; TOXOPLASMOSIS, CEREBRAL;

EID: 0034150015     PISSN: 1252607X     EISSN: None     Source Type: Journal    
DOI: 10.1051/parasite/2000071039     Document Type: Article

References (20)

1. ARAUJO F.G., HUSKINSON J. & REMINGTON J.S. Remarkable in vitro and in vivo activities of the hydroxynaphtoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 1991, 35, 293-299.
2. ARAUJO F.G., PROKOCIMER P., LIN T. & REMINGTON J. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrobial Agents and Chemotherapy, 1992, 36, 2454-2457.
3. ARAUJO F.G., KHAN A.A. & REMINGTON J.S. Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 1996, 40, 1335-1337.
4. ARAUJO F.G., KHAN A.A., SLIFER T.L., BRYSKIER A. & REMINGTON J. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrobial Agents and Chemotherapy, 1997, 41, 2137-2140.
5. BLAIS J., GARNEAU V. & CHAMBERLAND S. Inhibition of Toxoplasma gondii protein synthesis by azithromycin. Antimicrobial Agents and Chemotherapy, 1993a, 37, 1701-1703.
6. BLAIS J., TARDIF C. & CHAMBERLAND S. Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 1993b, 37, 2571-2577.
7. CARR A., TINDALL B., BREW B.J., MARRIOTT D.J., HARKNESS J.L., PENNY R. & COOPER D.A. Low-dose of trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Annals of Internal Medicine, 1992, 117, 106-111.
8. DE GANS J., PORTEGIES P., REISS P., TROOST D., VAN GOOL T. & LANGE J.M. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. Journal of Acquired Immune Deficiency Syndromes, 1992, 5, 137-142.
9. DEROUIN F., PIKETTY C., CHASTANG C., CHAU F., ROUVEIX B. & POCIDALO J.J. Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrobial Agents and Chemotherapy, 1991, 35, 252-255.
10. HARRIS C., SALGO M.P., TANOWTTZ H.B. & WITTNER M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. Journal of Infectious Disease, 1988, 157, 14-22.
11. HUSKINSON-MARK J., ARAUJO F.G. & REMINGTON J.S. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. Journal of Infectious Disease, 1991, 164, 170-177.
12. KHAN A.A., SLIFER T., ARAUJO F.G., POLZER R. & REMINGTON J. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. Antimicrobial Agents and Chemotherapy, 1997, 41, 893-897.
13. KLEPSER M.E. & KLEPSER T.B. Drug treatment of HIV-related opportunistic infections. Drugs, 1997, 53, 40-73.
14. LEPORT C., CHÊNE G., MORLAT P., LUFT B.J., ROUSSEAU F., PUEYO S., HAFNER R., MIRO J., AUBERTIN J., SALAMON R. & VILDE J.L. Pyrimethamine for primary prophylaxis of Toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. Journal of Infectious Diseases, 1996, 173, 91-97.
15. PAYEN M.C., DE WIT S., SOMMEREIJNS B. & CLUMECK N. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS. Biomedicine and Pharmacotherapy, 1997, 5, 439-445.
16. PERRY C.M. & BALFOUR J.A. Didanosine : an uptake on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs, 1996, 52, 928-962.
17. RICHARDS F.O., KOVACS J.A. & LUFT B.J. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clinical Infectious Diseases, 1995, 21, S49-56.
18. SARCIRON M.E., LAWTON P., SACCHARIN C., PETAVY A.F. & PEYRON F. Effects of 2′,3′-dideoxyinosine on Toxoplasma gondii cysts in mice. Antimicrobial Agents and Chemotherapy, 1997, 41, 1531-1536.
19. SARCIRON M.E., LAWTON P., PÉTAVY A.F. & PEYRON F. Alterations of Toxoplasma gondii induced by 2′,3′-dideoxyinosine in vitro. Journal of Parasitology, 1998, 84, 1055-1059.
20. WISELKA M.J., READ R. & FINCH R.G. Response to oral and intravenous azithromycin in a patient with Toxoplasma encephalitis and AIDS. Journal of Infection, 1996, 33, 227-229.